U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935031) titled 'A Study of IMS001 in Patients With Multiple Sclerosis' on Nov. 03.
Brief Summary: This study will evaluate the safety and tolerability of IMS001 and explore its possible effects in adults with multiple sclerosis. IMS001 is an investigational cell therapy consisting of mesenchymal-like stem cells derived from human embryonic stem cells.
The study plans to enroll 4 adults aged 18 to 65 years with relapsing-remitting or secondary progressive multiple sclerosis in China. Each participant will receive a single infusion of IMS001 into a vein. All participants will receive IMS001, and both participants and the study team will know which t...